In preclinical studies of IBD, GLP-1 agonists have been shown to improve colitis by significantly improving the colon’s weight-to-length ratio, lowering the histopathological score and reducing pro-inflammatory cytokines levels [56,57]. Here, GLP1R is linked to inflammatory bowel disease.